Shire's Gaucher drug gets fast-track status in Europe

11/24/2009 | Reuters

The European Medicines Agency granted fast-track designation to Shire's velaglucerase alfa, a drug candidate for Gaucher disease. The company submitted the drug, which could address a shortage of Genzyme's Cerezyme, to the FDA in September.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY